Expression of tumor-promoting Cyr61 is regulated by hTRA2-β1 and acidosis

Human Molecular Genetics

Volumn 20, Issue 12, 2011, Pages 2356-2365

  Hirschfeld, Marc ^a,b   Jaeger, Markus ^a   Buratti, Emanuele ^c   Stuani, Cristiana ^c   Grueneisen, Johannes ^a   Gitsch, Gerald ^a   Stickeler, Elmar ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN HTRA2 BETA1; UNCLASSIFIED DRUG;

ACIDITY; ALTERNATIVE RNA SPLICING; ARTICLE; CONTROLLED STUDY; CYR61 GENE; EXTRACELLULAR SPACE; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ACIDOSIS; ALTERNATIVE SPLICING; BLOTTING, WESTERN; CYSTEINE-RICH PROTEIN 61; DNA PRIMERS; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; NERVE TISSUE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS;

EID: 79957475859     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr128     Document Type: Article

References (44)

1. Buratti, E., Baralle, M. and Baralle, F.E. (2006) Defective splicing, disease and therapy: searching for master checkpoints in exon definition. Nucleic Acids Res., 34, 3494-3510.
2. Baralle, D., Lucassen, A. and Buratti, E. (2009) Missed threads. The impact of pre-mRNA splicing defects on clinical practice. EMBO Rep., 10, 810-816.
3. Bork, P. (1993) The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett., 327, 125-130.
4. O'Brien, T.P., Yang, G.P., Sanders, L. and Lau, L.F. (1990) Expression of cyr61, a growth factor-inducible immediate-early gene. Mol. Cell Biol., 10, 3569-3577.
5. Leask, A. and Abraham, D.J. (2006) All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J. Cell Sci., 119, 4803-4810.
6. Chen, Y. and Du, X.Y. (2007) Functional properties and intracellular signaling of CCN1/Cyr61. J. Cell Biochem., 100, 1337-1345.
7. Lau, L.F. and Lam, S.C. (1999) The CCN family of angiogenic regulators: the integrin connection. Exp. Cell Res., 248, 44-57.
8. O'Kelly, J., Chung, A., Lemp, N., Chumakova, K., Yin, D., Wang, H.J., Said, J., Gui, D., Miller, C.W., Karlan, B.Y. et al. (2008) Functional domains of CCN1 (Cyr61) regulate breast cancer progression. Int. J. Oncol., 33, 59-67.
9. Xie, D., Yin, D., Wang, H.J., Liu, G.T., Elashoff, R., Black, K. and Koeffler, H.P. (2004) Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin. Cancer Res., 10, 2072-2081.
10. Bleau, A.M., Planque, N. and Perbal, B. (2005) CCN proteins and cancer: two to tango. Front. Biosci., 10, 998-1009.
11. Abe, M. and Sato, Y. (2001) cDNA microarray analysis of the gene expression profile of VEGF-activated human umbilical vein endothelial cells. Angiogenesis, 4, 289-298.
12. Sampath, D., Winneker, R.C. and Zhang, Z. (2002) The angiogenic factor Cyr61 is induced by the progestin R5020 and is necessary for mammary adenocarcinoma cell growth. Endocrine, 18, 147-159.
13. Sampath, D., Winneker, R.C. and Zhang, Z. (2001) Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17beta-estradiol and overexpression in human breast cancer. Endocrinology, 142, 2540-2548.
14. Hirschfeld, M., Zur Hausen, A., Bettendorf, H., Jager, M. and Stickeler, E. (2009) Alternative splicing of Cyr61 is regulated by hypoxia and significantly changed in breast cancer. Cancer Res., 69, 2082-2090.
15. Si, W., Kang, Q., Luu, H.H., Park, J.K., Luo, Q., Song, W.X., Jiang, W., Luo, X., Li, X., Yin, H. et al. (2006) CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol. Cell Biol., 26, 2955-2964.
16. Lin, M.T., Chang, C.C., Chen, S.T., Chang, H.L., Su, J.L., Chau, Y.P. and Kuo, M.L. (2004) Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J. Biol. Chem., 279, 24015-24023.
17. Harris, A.L. (2002) Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2, 38-47.
18. Gatenby, R.A., Gawlinski, E.T., Gmitro, A.F., Kaylor, B. and Gillies, R.J. (2006) Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res., 66, 5216-5223.
19. Brahimi-Horn,M.C., Chiche, J. and Pouyssegur, J. (2007) Hypoxia signalling controls metabolic demand. Curr. Opin. Cell Biol., 19, 223-229.
20. Elias, A.P. and Dias, S. (2008) Microenvironment changes (in pH) affect VEGF alternative splicing. Cancer Microenviron., 1, 131-139.
21. Johannes, G., Carter, M.S., Eisen, M.B., Brown, P.O. and Sarnow, P. (1999) Identification of eukaryotic mRNAs that are translated at reduced cap binding complex eIF4F concentrations using a cDNA microarray. PNAS, 96, 13118-13123.
22. Spriggs, K.A., Stoneley, M., Bushell, M. and Willis, A.E. (2008) Re-programming of translation following cell stress allows IRES-mediated translation to predominate. Biol. Cell, 100, 27-38.
23. Lareau, L.F., Green, R.E., Bhatnagar, R.S. and Brenner, S.E. (2004) The evolving roles of alternative splicing. Curr. Opin. Struct. Biol., 14, 273-282.
24. Stamm, S., Ben-Ari, S., Rafalska, I., Tang, Y., Zhang, Z., Toiber, D., Thanaraj, T.A. and Soreq, H. (2005) Function of alternative splicing. Gene, 344, 1-20.
25. Stoilov, P., Daoud, R., Nayler, O. and Stamm, S. (2004) Human tra2-beta1 autoregulates its protein concentration by influencing alternative splicing of its pre-mRNA. Hum. Mol. Genet., 13, 509-524.
26. Nayler, O., Cap, C. and Stamm, S. (1998) Human transformer-2-beta gene (SFRS10): complete nucleotide sequence, chromosomal localization, and generation of a tissue-specific isoform. Genomics, 53, 191-202.
27. Stamm, S., Zhu, J., Nakai, K., Stoilov, P., Stoss, O. and Zhang, M.Q. (2000) An alternative-exon database and its statistical analysis. DNA Cell Biol., 19, 739-756.
28. Daoud, R., Mies, G., Smialowska, A., Olah, L., Hossmann, K.A. and Stamm, S. (2002) Ischemia induces a translocation of the splicing factor tra2-beta 1 and changes alternative splicing patterns in the brain. J. Neurosci., 22, 5889-5899.
29. Yuan, Y., Hilliard, G., Ferguson, T. and Millhorn, D.E. (2003) Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J. Biol. Chem., 278, 15911-15916.
30. Watermann, D.O., Tang, Y., Zur Hausen, A., Jager, M., Stamm, S. and Stickeler, E. (2006) Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene. Cancer Res., 66, 4774-4780.
31. Fischer, D.C., Noack, K., Runnebaum, I.B., Watermann, D.O., Kieback, D.G., Stamm, S. and Stickeler, E. (2004) Expression of splicing factors in human ovarian cancer. Oncol. Rep., 11, 1085-1090.
32. Gabriel, B., Zur Hausen, A., Bouda, J., Boudova, L., Koprivova, M., Hirschfeld, M., Jager, M. and Stickeler, E. (2009) Significance of nuclear hTra2-beta1 expression in cervical cancer. Acta Obstet. Gynecol. Scand., 88, 216-221.
33. Tsuda, K., Someya, T., Kuwasako, K., Takahashi, M., He, F., Unzai, S., Inoue, M., Harada, T., Watanabe, S., Terada, T. et al. (2010) Structural basis for the dual RNA-recognition modes of human Tra2-{beta} RRM. Nucleic Acids Res., 39, 1538-1553.
34. Novoyatleva, T., Heinrich, B., Tang, Y., Benderska, N., Butchbach, M.E., Lorson, C.L., Lorson, M.A., Ben-Dov, C., Fehlbaum, P., Bracco, L. et al. (2008) Protein phosphatase 1 binds to the RNA recognition motif of several splicing factors and regulates alternative pre-mRNA processing. Hum. Mol. Genet., 17, 52-70.
35. Sciabica, K.S. and Hertel, K.J. (2006) The splicing regulators Tra and Tra2 are unusually potent activators of pre-mRNA splicing. Nucleic Acids Res., 34, 6612-6620.
36. Izumi, H., Torigoe, T., Ishiguchi, H., Uramoto, H., Yoshida, Y., Tanabe, M., Ise, T., Murakami, T., Yoshida, T., Nomoto, M. et al. (2003) Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat. Rev., 29, 541-549.
37. Hockel, M. and Vaupel, P. (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl Cancer Inst., 93, 266-276.
38. Leu, S.J., Lam, S.C. and Lau, L.F. (2002) Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells. J. Biol. Chem., 277, 46248-46255.
39. Menendez, J.A., Mehmi, I., Griggs, D.W. and Lupu, R. (2003) The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr. Relat. Cancer, 10, 141-152.
40. Romano, M., Marcucci, R. and Baralle, F.E. (2001) Splicing of constitutive upstream introns is essential for the recognition of intra-exonic suboptimal splice sites in the thrombopoietin gene. Nucleic Acids Res., 29, 886-894.
41. Qi, J., Su, S. and Mattox, W. (2007) The doublesex splicing enhancer components Tra2 and Rbp1 also repress splicing through an intronic silencer. Mol. Cell Biol., 27, 699-708.
42. Hofmann, Y., Lorson, C.L., Stamm, S., Androphy, E.J. and Wirth, B. (2000) Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). PNAS, 97, 9618-9623.
43. Schagger, H. and von Jagow, G. (1987) Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal. Biochem., 166, 368-379.
44. Buratti, E., Baralle, M., De Conti, L., Baralle, D., Romano, M., Ayala, Y.M. and Baralle, F.E. (2004) hnRNP H binding at the 5' splice site correlates with the pathological effect of two intronic mutations in the NF-1 and TSHbeta genes. Nucleic Acids Res., 32, 4224-4236.